David Peritt

Title: **David Peritt: Innovator in Immunology with 30 Patents**

Introduction

David Peritt, based in Bala Cynwyd, Pennsylvania, is a notable inventor with a remarkable portfolio of 30 patents. His work primarily focuses on advancements in immunology, particularly in the functioning and application of apoptotic cells and their role in immune regulation.

Latest Patents

Among David's latest contributions to the field are two significant patents. The first patent involves the use of apoptotic cells ex vivo to generate regulatory T cells. This patent discusses the capacity of professional phagocytes, or antigen presenting cells (APCs), to recognize and remove apoptotic cells. These processes are facilitated by a sophisticated system of molecular-pattern receptors that bind to apoptotic-cell-associated patterns, enabling efficient immune response management. His second patent outlines a method for treating lupus by administering an anti-IL-12 antibody. This innovation encompasses isolated antibodies and methods for their production, targeting IL-12 related conditions, notably systemic lupus erythematosus.

Career Highlights

David has lent his expertise to prominent organizations, including Janssen Biotech, Inc. and Centocor, Inc. His contributions in these companies have significantly contributed to the advancement of therapeutic solutions in immunology.

Collaborations

Throughout his career, David has collaborated with notable professionals such as Jill M. Giles-Komar and David M. Knight. These partnerships have enriched his research endeavors and enhanced the development of his innovative solutions.

Conclusion

David Peritt stands out as an influential inventor in the realm of immunology, with a diverse set of patents that showcase his innovative approaches to complex biological challenges. His work remains vital in shaping future therapies and advancing our understanding of immune system function.